Recommendations of the SEC (Endocrinology & Metabolism) made in its 82nd meeting held on 21.12.2021& 22.12.2021 at CDSCO HQ New Delhi:

S.No	File Name & Drug Name, Strength	Firm Name	Recommendations
New Drugs Division			
1.	DPP4 Inhibitors	PvPI, IPC	The recommendation of signal review panel, PvPI was placed before the committee. After detailed deliberation, the committee recommended that CDSCO may request State Drugs Controllers to direct the manufacturers of the drug to include DPP4 inhibitors induced Arthralgia in the package insert of the drug.
2.	ND/MA/21/000177 Lobeglitazone 0.5 mg tablet	M/s. Macleods Pharmaceuticals Ltd	The firm presented the proposal of Phase III clinical trial protocol along with BE Study protocol before the committee. The committee noted that the proposed clinical trial is a comparative study of Lobeglitazone 0.5 mg OD Vs Pioglitazone 15 mg OD with background treatment with Metformin ≥1000 mg/day After detailed deliberation, the committee recommended for grant of permission to conduct the BE study. The firm should submit BE Study report along with the revised CT protocol with inclusion criteria of subjects with background treatment with Metformin ≥1500 mg/day and with cardiology parameters.
3.	ND/IMP/21/000046 Intravenous Fat Emulsion for Infusion 20% (Brand Name-Intralipid 20%)	M/s. Fresenius Kabi India Pvt. Ltd	The firm presented the data for fulfilling the condition of import and marketing of the drug Intravenous Fat emulsion 20% (Intralipid 20%) before the committee. After detailed deliberation, the committee recommended for continued import and marketing of the drug in the country.
Biological Division			
4.	4-81/Cadila/PAC-R-Teripratide/17-BD Teriparatide	M/s. Cadila Healthcare Pvt Ltd	The firm presented the proposal for updation in the package insert. After detailed deliberation, the committee recommended that the firm should present the differences between Indian and innovator package insert for further evaluation.

S.No	File Name & Drug Name, Strength	Firm Name	Recommendations
5.	X-11026/261/2021-BD Insulin Glargine (100 IU OR 300 IU)	M/s. Sanofi India Limited	In light of earlier SEC recommendation dated 26.10.2021, the firm presented their proposal for conduct of observational study with insulin glargine. After detailed deliberation, the committee recommended for grant of permission to conduct the study as per the protocol presented by the firm.
6.	BIO/IMP/21/000043 Fixed Ratio Combination of Insulin Glargine and Lixisenatide (100U + 50µg /33µg)	M/s. Sanofi India Limited	In light of the SEC meeting dated 24.08.2021 & 25.08.2021, the firm presented justifications and sub-group analysis of trial outcomes and for their proposal for grant of marketing authorization of the Fixed Ratio combination with clinical trial data generated globally and in India. After detailed deliberation, the committee reiterated its earlier decision and did not recommend for grant of marketing authorization for the product.
7.	BIO/IMP/20/000058 Insulin Lispro Ultrarapid Injection	M/s. Eli Lilly and Company Pvt. Ltd.	The firm presented their proposal for amendment in the warning statement. The committee observed that the drug contains Treprostinil Sodium as novel excipient and there is lack of adequate safety data for the drug in India. After detailed deliberation, the committee did not recommend for amendment in the warning statement at this stage.
8.	BIO/CT/21/000002 Insulin Injection 100 IU/ml	M/s. Hinge Clinica	The firm presented the protocol for grant of permission to conduct Phase III clinical trial. After detailed deliberation, the committee recommended that the firm should revise the protocol with respect to following for further consideration:- 1. Present the results of the clamp study 2. The inclusion criteria should be revised to include type I diabetes mellitus. 3. Fasting C-peptide range should be specified. 4. In Type I diabetes patients, requirements for basal insulin should be specified.

S.No	File Name & Drug Name, Strength	Firm Name	Recommendations
			Accordingly, the firm should submit the revised protocol for review by the committee.
SND Division			
9.	SND/MA/21/000453 Cholecalciferol Sachets 60,000 IU	M/s. Akums Pharmaceuticals	The firm presented their proposal of Cholecalciferol Sachets 60,000 IU before the committee. After detailed deliberation, the committee opined that the firm should submit detailed technical justification for BE study waiver along with the feasibility and technical data for further consideration.
10.	SND/MA/19/000099 Vildagliptin Sustained Release (SR) Tablets 100 mg	M/s. Exemed Pharmaceuticals	The firm presented the active PMS study protocol for Vildagliptin Sustained Release (SR) Tablets 100 mg as per the condition of Form CT-23. After detailed deliberation, the committee recommended for grant of permission for conduct of the active PMS study subject to condition that the firm should conduct laboratory investigations for LFT, KFT, Serum Lipase and Amylase etc at 12 week and 24 week. Accordingly, the firm should submit the revised protocol to CDSCO prior to initiation of the study.
11.	SND/MA/21/000505 Vitamin D3 Oral solution 60000IU	M/s. Ravenbhel Healthcare	The firm presented the proposal along with justification for BE study and clinical trial waiver. After detailed deliberation, the committee recommended for grant of permission to manufacture and market Vitamin D3 Oral solution 60000 IU.
12.	SND/MA/21/000525 Liraglutide 6mg/ml solution for injection in pre-filled pen (18mg/3ml pre-filled pen) (Synthetic Peptide)	M/s. Biocon Pharma Limited	The firm presented their proposal of Liraglutide 6mg/ml solution for injection in pre-filled pen (18mg/3ml pre-filled pen) (Synthetic Peptide) alongwith BE study protocol before the committee. After detailed deliberation, the committee recommended for grant of permission to conduct the respective BE study as per the protocol presented.

S.No	File Name & Drug Name, Strength	Firm Name	Recommendations
13.	SND/MA/19/000114 Vildagliptin Sustained Release Tablet 100mg	M/s. Abbott Healthcare	The firm didn't turn up for presentation.
FDC Division			
14.	FDC/MA/21/000026 Dapagliflozin 5mg/10mg+ Teneligliptin20mg/20 mgFilm Coated Tablet	M/s. Synokem Pharmaceuticals Ltd	The firm presented their BE study report before the committee. After detailed deliberation, the committee recommended for initiation of Phase III clinical trial for which permission has already been issued by CDSCO.
15.	FDC/MA/21/000214 Metformin Hydrochloride (as sustained release) 1000mg/500mg+ Teneligliptin Hydrobromide Hydrate Eq. to Teneligliptin 20mg/20mg +Dapagliflozin Propanediol Monohydrate Eq. to Dapoagliflozin 10mg /5mg Tablets	M/s. Ravenbhel Healthcare Pvt. Ltd	The firm presented their proposal alongwith BE and Phase III clinical trial protocol. After detailed deliberation, the committee recommended for grant of permission to conduct the BE study. With regard to phase III CT protocol, the committee opined that: 1. The firm should enroll 328 evaluable patients 2. The reference arms should be revised to FDC of Dapagliflozin 10 mg + Metformin (SR) 1000mg tablets, and FDC of Teneligliptin 20 mg + Metformin (SR) 1000mg tablets. 3. More government sites should be included in the study. In view of above, the Committee recommended that firm should submit the revised CT protocol to CDSCO for approval.
16.	FDC/MA/21/000274 Dapagliflozin + Sitagliptin +Metformin HCL (ER) (10 mg + 50mg + 500mg, 10 mg + 50mg + 1000mg& 10mg + 100mg + 100mg)	M/s. Zydus	The firm presented their proposal alongwith BE and Phase III CT study protocol. After detailed deliberation, the committee recommended for conducting the proposed BE study. With regard to Phase III CT protocol, the firm presented the CT protocol in higher strength only. The Committee noted that : 1. The firm has applied in various strengths for manufacturing and marketing and did not provide any adequate justification for not including the same in the study protocol. 2. One more Arm i.e FDC of Sitagliptin100mg + Metformin 1000mg SR

S.No	File Name & Drug Name, Strength	Firm Name	Recommendations
			needs to be included and accordingly inclusion and exclusion and other criteria need to be revised. In view of above, the committee recommended that the firm should submit the revised protocol for further review by the committee.
17.	FDC/MA/21/000093 Remogliflozin etabonate 100mg/100mg +Vildagliptin 50mg/50mg+ Metformin Hydrochloride 500mg /1000mg tablet	M/s. Glenmark Pharmaceuticals Ltd	In light of the SEC recommendations, the firm presented Phase IV CT protocol before the committee. After detailed deliberation, the committee opined that : 1. The primary objective of the study should be safety. 2. HbA1C level should be ≥ 8% 3. More government sites should be included in the study. In view of above, the Committee recommended that firm should submit the revised protocol for further review by the Committee.
18.	FDC/MA/21/000083 Glimepiride IP +Voglibose IP + Metformin HCL IP (as sustained release) IP (1mg+ 0.2mg+ 1000mg & 2 mg + 0.2 mg+1000mg)Tablets	M/s. Swiss Garnier	In light of the recommendations of SEC, the firm presented the BE study report. After detailed deliberation, the committee recommended for grant of permission to manufacture and market the proposed additional strengths of the FDC with the condition that firm should conduct Phase IV clinical trial and protocol should be submitted within 3 months of approval.
GCT Division			
19.	CT/74/20 Online Submission (12686) Insulin icodec and once daily insulin glargine 100 units/ml	M/s. Novo-Nordisk	The firm presented the proposed protocol NN1436-4477, Amendment Version 4.0 dated 30NOV2020 before the committee. After detailed deliberation, the committee recommended for conduct of the trial as per the presented amended protocol.
20.	CT/134/21 Online Submission (28510) Alpelisib (BYL719)	M/s. Novartis	The firm presented the proposed Phase II global clinical trial study protocol no. CBYL719C2202, Version: 01; dated 06Aug2021 before the Committee. **Risk versus benefit:** The non clinical and clinical studies with Alpelisib (BYL719) was approved by USFDA, India, EU and

S.No	File Name & Drug Name, Strength	Firm Name	Recommendations
			other countries in combination with Fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen. The Dapagliflozin and Metformin are anti-diabetic and both were approved. Thus it justifies the conduct of trial. **Innovations Vs existing therapeutic option:** This is a Phase II, multicenter, randomized, open-label, active-controlled trial designed to assess the safety and efficacy of the combination of Dapagliflozin plus Metformin XR compared with Metformin XR during treatment with Alpelisib plus Fulvestrant in participants with HR-positive, HER2-negative advanced breast cancer with a PIK3CA mutation following progression on or after endocrine-based therapy. **Unmet need:** The study will investigate the management strategies that offer early (prophylactic) and sustained improvement of hyperglycemia than what is achieved with Metformin and/or Dapagliflozin as initial therapy after hyperglycemia has been observed. After detailed deliberation, the Committee recommended for the conduct of the proposed study with the following conditions, that: **1)** The firm should provide continuous glucose monitoring (CGM) to the trial site for the continuous monitoring of each subject flash glucose in addition to the protocol defined fasting blood glucose (FBG) monitoring, to safeguard the trial subjects. **2)** DEXA Bone scan to be performed at screening and those found with high fracture risk (FRAX) should be excluded. **3)** Regular clinical investigation/test to be performed to control the UTI risk with the trial subjects. **4)** The trial should have atleast 50% Govt. site. **5)** The study team should mandatorily have

S.No	File Name & Drug Name, Strength	Firm Name	Recommendations
			one DM-Endo. / MD (Diabetologist or Medicine) as Co-Investigator/Sub-Investigator at each site.